-DOCSTART- -X- O
Middle -X- _ O
East -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
MERS -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
emerging -X- _ O
infectious -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
MERS -X- _ B-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
MERS-CoV -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
The -X- _ O
continuous -X- _ O
increase -X- _ O
of -X- _ O
MERS -X- _ O
cases -X- _ O
has -X- _ O
posed -X- _ O
a -X- _ O
serious -X- _ O
threat -X- _ O
to -X- _ O
public -X- _ O
health -X- _ O
worldwide -X- _ O
, -X- _ O
calling -X- _ O
for -X- _ O
development -X- _ O
of -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
MERS -X- _ O
vaccines. -X- _ O
We -X- _ O
have -X- _ O
previously -X- _ O
shown -X- _ O
that -X- _ O
a -X- _ O
recombinant -X- _ O
protein -X- _ O
containing -X- _ O
residues -X- _ O
377–588 -X- _ O
of -X- _ O
MERS-CoV -X- _ O
receptor- -X- _ O
binding -X- _ O
domain -X- _ O
( -X- _ O
RBD -X- _ O
) -X- _ O
fused -X- _ O
with -X- _ O
human -X- _ O
Fc -X- _ O
( -X- _ O
S377-588-Fc -X- _ O
) -X- _ O
induced -X- _ O
highly -X- _ O
potent -X- _ O
anti-MERS-CoV -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
in -X- _ O
the -X- _ O
presence -X- _ O
of -X- _ O
MF59 -X- _ O
adjuvant. -X- _ O
Here -X- _ O
we -X- _ O
optimized -X- _ O
the -X- _ O
doses -X- _ O
of -X- _ O
S377-588-Fc -X- _ B-Intervention
using -X- _ I-Intervention
MF59 -X- _ I-Intervention
as -X- _ I-Intervention
an -X- _ I-Intervention
adjuvant -X- _ I-Intervention
in -X- _ O
order -X- _ O
to -X- _ O
elicit -X- _ O
strong -X- _ O
immune -X- _ O
responses -X- _ O
with -X- _ O
minimal -X- _ O
amount -X- _ O
of -X- _ O
antigen. -X- _ O
Our -X- _ O
results -X- _ O
showed -X- _ O
that -X- _ O
S377-588-Fc -X- _ B-Outcome
at -X- _ I-Outcome
1 -X- _ I-Outcome
μg -X- _ I-Outcome
was -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
immunized -X- _ I-Outcome
mice -X- _ I-Outcome
potent -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses. -X- _ I-Outcome
Particularly -X- _ I-Outcome
, -X- _ I-Outcome
S377-588-Fc -X- _ I-Outcome
at -X- _ I-Outcome
1 -X- _ I-Outcome
μg -X- _ I-Outcome
elicited -X- _ I-Outcome
strong -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
against -X- _ I-Outcome
both -X- _ I-Outcome
pseudotyped -X- _ I-Outcome
and -X- _ I-Outcome
live -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
similar -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
induced -X- _ I-Outcome
at -X- _ I-Outcome
5 -X- _ I-Outcome
and -X- _ I-Outcome
20 -X- _ I-Outcome
μg -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
this -X- _ O
RBD-based -X- _ O
subunit -X- _ O
MERS -X- _ O
vaccine -X- _ O
candidate -X- _ O
at -X- _ O
the -X- _ O
dose -X- _ O
as -X- _ O
low -X- _ O
as -X- _ O
one -X- _ B-Outcome
μg -X- _ I-Outcome
is -X- _ I-Outcome
sufficiently -X- _ I-Outcome
potent -X- _ I-Outcome
to -X- _ I-Outcome
induce -X- _ I-Outcome
strong -X- _ I-Outcome
humoral -X- _ I-Outcome
and -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ O
against -X- _ O
MERS- -X- _ O
CoV -X- _ O
infection -X- _ O
, -X- _ O
thus -X- _ O
providing -X- _ O
guidance -X- _ O
for -X- _ O
determining -X- _ O
the -X- _ O
optimal -X- _ O
dosage -X- _ O
of -X- _ O
RBD-based -X- _ O
MERS -X- _ O
vaccines -X- _ O
in -X- _ O
the -X- _ O
future -X- _ O
clinical -X- _ O
trials -X- _ O
and -X- _ O
for -X- _ O
applying -X- _ O
the -X- _ O
dose-sparing -X- _ O
strategy -X- _ O
in -X- _ O
other -X- _ O
subunit -X- _ O
vaccine -X- _ O
trials -X- _ O
. -X- _ O

